Handelsbanken Fonder
BBIO icon

Handelsbanken Fonder’s BridgeBio Pharma BBIO Stock Holding History

Handelsbanken Fonder’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.27M Sell
43,850
-1,000
-2% -$70K 0.01% 634
2026
Q1 		$3.33M Buy
44,850
+6,900
+18% +$500K 0.01% 578
2025
Q4 		$2.9M Buy
37,950
+3,300
+10% +$217K 0.01% 623
2025
Q3 		$1.8M Hold
34,650
– – 0.01% 766
2025
Q2 		$1.5M Sell
34,650
-3,300
-9% -$120K 0.01% 772
2025
Q1 		$1.31M Hold
37,950
– – 0.01% 828
2024
Q4 		$1.04M Buy
37,950
+5,400
+17% +$140K ﹤0.01% 949
2024
Q3 		$829K Buy
32,550
+4,900
+18% +$129K ﹤0.01% 1016
2024
Q2 		$700K Buy
27,650
+1,300
+5% +$35.5K ﹤0.01% 1001
2024
Q1 		$815K Hold
26,350
– – ﹤0.01% 931
2023
Q4 		$1.06M Buy
26,350
+1,600
+6% +$48.1K 0.01% 769
2023
Q3 		$653K Buy
24,750
+1,000
+4% +$28.4K ﹤0.01% 925
2023
Q2 		$408K Hold
23,750
– – ﹤0.01% 1177
2023
Q1 		$394K Hold
23,750
– – ﹤0.01% 1128
2022
Q4 		$181K Buy
23,750
+3,800
+19% +$36.4K ﹤0.01% 1455
2022
Q3 		$198K Hold
19,950
– – ﹤0.01% 1436
2022
Q2 		$181K Hold
19,950
– – ﹤0.01% 1512
2022
Q1 		$202K Hold
19,950
– – ﹤0.01% 1632
2021
Q4 		$333K Sell
19,950
-4,800
-19% -$203K ﹤0.01% 1578
2021
Q3 		$1.16M Buy
24,750
+3,800
+18% +$204K 0.01% 828
2021
Q2 		$1.28M Buy
20,950
+1,800
+9% +$103K 0.01% 795
2021
Q1 		$1.18M Buy
19,150
+5,550
+41% +$363K 0.01% 768
2020
Q4 		$967K Hold
13,600
– – 0.01% 842
2020
Q3 		$510K Hold
13,600
– – ﹤0.01% 980
2020
Q2 		$443K Buy
+13,600
New +$414K ﹤0.01% 1016

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Handelsbanken Fonder's BBIO Position: Q2 2026 in Review

Handelsbanken Fonder reduced its BridgeBio Pharma (BBIO) stake by 2.2% in Q2 2026, selling an estimated $70K and leaving 43,850 shares worth $3.27M. The position accounts for 0.01% of the portfolio, ranked #634.

Handelsbanken Fonder first reported a position in BBIO in Q2 2020 and has held it in 25 quarters since. The position peaked at $3.33M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Handelsbanken Fonder held 43,850 shares of BridgeBio Pharma worth $3.27M as of Q2 2026.
  • Handelsbanken Fonder sold 1,000 BridgeBio Pharma shares in Q2 2026, an estimated $70K.
  • BridgeBio Pharma made up 0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #634 holding.
  • Handelsbanken Fonder first reported a position in BridgeBio Pharma in Q2 2020 and has held it in 25 quarters since.
  • Handelsbanken Fonder's BridgeBio Pharma position peaked at $3.33M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.